Interstitial lung disease (ILD) encompasses a diverse group of parenchymal lung disorders that are inherently progressive and fatal. Current treatment recommendations for mild-to-moderate impairment in ILD involve a combination of pharmacologic treatment and supportive care. Nintedanib and pirfenidone have emerged as first-line treatment for ILD, as they have been shown to slow or arrest the progression of ILD, which is the main goal of treatment. Nintedanib and pirfenidone are available through specialty pharmacies, but all pharmacists and prescribers should be prepared to appropriately interpret and navigate drug interactions with these agents in any practice setting.
|Original language||English (US)|
|Specialist publication||U.S. Pharmacist|
|State||Published - Jul 2022|
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science